SCHEMBL191828

SCHEMBL191828

Cc1csc(Nc2cc(Oc3ccccc3Cl)ccn2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 12/20 0.54
KCNN1 Q92952 1/20 0.46
KCNN2 Q9H2S1 1/20 0.46
KCNN3 Q9UGI6 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
SLC2A1 P11166 1/20 0.46
GRM5 P41594 2/20 0.44
SCD O00767 1/20 0.44
TRPV4 Q9HBA0 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191171 0.87 GRM5 (0.45) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL190435 0.87 GAA (0.56) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL190467 0.86 GCK (0.54) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL190775 0.85 GCK (0.53) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL190659 0.84 GCK (0.59) GCKKCNN1KCNN2KCNN3GAA
SCHEMBL191023 0.84 GRM5 (0.43) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL190648 0.84 GCK (0.66) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL12305625 0.84 GCK (0.51) GCKKCNN1KCNN2KCNN3ALDH1A1
SCHEMBL190111 0.83 GCK (0.53) GCKGRM5
SCHEMBL12305664 0.82 GAA (0.48) GCKGAAGRM5SCDTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
CN-101437512-A Glucokinase activators ARRAY BIOPHARMA INC (US) 2009-05-20 CN disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885KCNN1 1454/4885KCNN2 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.